VitaLink Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$10,052	1
2023	Research	$79,414	11
2022	Research	$21,553	4
2021	Research	$97,497	7
2020	Research	$104,667	9
2019	Research	$7,552	22

Breakdown

Who paid Research payments · program years 2019–2024

AstraZeneca Pharmaceuticals LP $114,043 10 payments
Novartis Pharmaceuticals Corporation $87,761 8 payments
Mylan Specialty L.P. $86,437 10 payments
Merck Sharp & Dohme Corporation $22,800 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $8,012 3 payments
Cipla USA Inc. $1,515 21 payments
Moderna TX, Inc. $167 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $76,385 9 payments
A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $71,712 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $63,989 1 payment
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $29,986 4 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $22,800 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $14,469 1 payment
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $10,052 1 payment
Tio & Olo versus PBO stratified by PIFR $8,012 3 payments
A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 $6,933 2 payments
A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard-Of-Care Asthma Therapy in Patients With Uncontrolled Asthma $6,114 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.